Company: INDP
Filing Date: 2025-02-05
Form Type: S-3
Source: 0001493152-25-005016
Chunk: 20

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-05
Form: S-3
Chunk 20
---
      
 the voting power of the common stock;                                         |
| ● | impairing                                                                     
 the liquidation rights of the common stock; or                                |
| ● | delaying                                                                      
 or preventing a change in control without further action by the stockholders. |

As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock. There is no current intention for us to issue any shares of preferred stock.

Private Placement Warrants

We issued investors in the January 2025 Private Placement investor warrants to purchase up to an aggregate of 2,109,383 shares of common stock at an exercise price equal to $0.94 per share (subject to standard adjustments for stock splits, stock dividend, rights offerings and pro rata distributions). We also issued to designees of the placement agent in the January 2025 Private Placement, placement agent warrants to purchase up to an aggregate of 147,656 shares of common stock at an exercise price equal to $1.175 per share (subject to standard adjustments for stock splits, stock dividend, rights offerings and pro rata distributions).

Duration and Exercise Price

The investor warrants have an exercise price of $0.94 per share while the placement warrants have an exercise price of $1.175 per share and were exercisable upon issuance. The warrants will expire five years following their issuance. The warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

Exercise Limitation

A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder would beneficially own more than 4.99% or 9.99%, depending on the individual investor, of the outstanding common stock immediately after exercise (the “Beneficial Ownership Limitation”), except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the Beneficial Ownership Limitation, provided that the Beneficial Ownership Limitation in no event exceeds 19.99%. No fractional shares of common stock will be issued in connection with the exercise of warrants. In lieu of fractional shares, we will pay the holder either an amount in cash equal to the fractional amount multiplied by the exercise price or round such fractional share to a whole share.

Cashless Exercise

In lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may, in the event the shares underlying the warrant